

Chordate Medical presents interim report for Q2 2022

Chordate Medical Holding (publ) publishes its interim report for Q2 2022 on Tuesday, August 30, 2022, 08:30. On Wednesday, August 31 at 11:00 am, the company invites you to a teleconference with CEO Anders Weilandt.

After the conference, there will be a question-and-answer session. The presentation is held in English. It is possible to follow the conference via computer or mobile devices.

To register for the web conference, register via the following link:

<https://attendee.gotowebinar.com/register/3519820819663201294>

The number of places is limited, so we recommend registering well in advance to secure a place.

A recording of the web conference will be available after the conference on the company's website www.chordate.com and on the Västra Hamnen Corporate Finance [YouTube channel](#).

For more information, please contact:

Anders Weilandt, CEO

anders.weilandt@chordate.com

Cell: +46 733-874277

About Chordate

Chordate Medical Holding AB (publ) is a medical technology company that for over ten years has developed, patented and CE-marked a new neuromodulation treatment technology for chronic nasal congestion (rhinitis) and chronic migraine. The company offers its product via distributors to clinics and hospitals in the Nordics, Germany, the UK, Israel, and Saudi Arabia. Chordate Medical's share is listed on Nasdaq First North Growth Market Stockholm (ticker: CMH). Read more at www.chordate.com/en/

Chordate's Certified Adviser on Nasdaq First North Growth Market Stockholm is Västra Hamnen Corporate Finance AB, +46 40 200 250, ca@vhcorp.se.

N.B. The English text is an in-house translation of the original Swedish text. Should there be any disparities between the Swedish and the English text, the Swedish text shall prevail.

Attachments

[Chordate Medical presents interim report for Q2 2022](#)